SYRE - Spyre Therapeutics, Inc. Latest News | Finranks

07.08.2026

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units (“RSUs”) to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on August 3, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

05.08.2026

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.

04.08.2026

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), demonstrating best-in-class efficacy potential and a safety profile consistent with in-class comparators

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
SYRE	Wolfe Research	Peer Perform	undefined >> undefined	July 28th 2026

Press releases

07.08.2026

Spyre Therapeutics, Inc. (SYRE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Announces Grants of Inducement Awards

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Upgrades / Downgrades

Press releases

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Spyre Therapeutics, Inc. (SYRE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Announces Grants of Inducement Awards

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Upgrades / Downgrades

Press releases

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update